Skip to content

Tesamorelin / Tesmorelin

Emerging evidence

Tesamorelin is a growth hormone–releasing hormone (GHRH) analog. It is FDA-approved for HIV-associated lipodystrophy, giving providers clinical familiarity. Not medical advice; consult a provider.

How Tesamorelin / Tesmorelin works

Tesamorelin stimulates GH release via GHRH receptors. It has human clinical trial data in specific populations. Dosing and monitoring must be provider-directed.

Researched benefits

  • •FDA history for specific indication
  • •May support visceral fat and body composition in research
  • •GHRH mechanism distinct from GHRPs
  • •Provider familiarity in some settings

What it is studied for

  • •Body composition in research contexts
  • •Growth hormone support when GHRH pathway preferred
  • •Often used in combination with other secretagogues under provider oversight

Reported side effects and cautions

  • •Injection-site reactions
  • •GH-related effects; IGF-1 and glucose monitoring recommended
  • •Contraindicated in active cancer; use only under provider care

Evidence rating: Emerging evidence

Some human data exists but the evidence base is limited — often small studies, narrow indications, or trials still under way.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Tesamorelin / Tesmorelin. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.